Company profiles

 

Takeda Oncology is the brand for the global oncology business unit of Takeda Pharmaceutical Company Limited. We aspire to cure cancer by delivering novel medicines to meet the unique and urgent needs of people living with cancer, their loved ones and the health care providers who support them around the world. Additional information about Takeda Oncology is available at www.takedaoncology.com


 

  

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visit: www.amgen.com and follow us on: www.twitter.com/amgen

 
 
 

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. We seek to deliver truly innovative and life-changing drugs for our patients through the discovery, development, and commercialization of products for cancer and other severe, immune, inflammatory conditions. Celgene employs more than 5,300 employees worldwide. Visit: www.celgene.com

 
 
 

Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, incl. oncology, immunology, neuroscience, infectious disease and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders.. More info on www.janssen-emea.com

 

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 119,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com


 
   

Neopharm Israel is dedicated to bringing solutions to patients suffering from life-threatening diseases with unmet medical needs around the world, while creating maximum value for our patients, customers, business partners, employees and shareholders.  For more information, please visit: www.neopharmisrael.com


 

Neovii is an independent, global biopharmaceutical company with a patient-focused mission to develop and bring to market novel life-transforming therapies to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders. Neovii was founded in 2013 by te acquisition of Fresenius Biotech inheriting more than three decades of experience in speciality pharmaecuticals. Neovii's global headquarters are located in Rapperswil, Switzerland, its U.S headquarters are in Waltham, MA, and its biologics manufacturing site and German operations are located in Gräfelfing, Germany. Neovii employs approx. 150 employees and has presence in nearly 60 countries worldwide. Visit: www.neovii.com

 
 

   
 

Sigma-tau Research Switzerland S.A. (Mendrisio, CH) is actively engaged in the development of innovative treatments for rare diseases. More specifically in the hematologic malignancies arena, sigma-tau Research Switzerland is developing Roneparstat (SST0001), a microenvironment modulator via the specific inhibition of the enzyme heparanase currently completing phase I, as a new potential therapeutic agent for multiple myeloma. Visit: www.sigma-tau.it

 

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme.

Sanofi has a strong heritage in oncology research, and notably in chemotherapy. Its aim is to combat cancer in all its different forms by carrying out research on the different pathways involved in the development, growth and propagation of cancer cells. The oncology R&D portfolio contains a range of innovative therapeutic agents with different mechanisms of action. Through collaborations focusing on novel therapeutic approaches including immuno-oncology, we reinforced our presence in this area. Visit: http://en.sanofi.com

 
 

  

Binding Site is committed to improving patient lives worldwide through education, collaboration and innovation. Discover how your Multiple Myeloma patients could benefit from Binding Site's Freelite® and Hevylite® assays and specialist analyers including the new Optilite.

Freelite is the ONLY serum free light chain test recommended by international and national guidelines supported by more than 15 years of clinical evidence. The complimentary 'Hevylite' test adds additional information for "difficult-to-monitor" myeloma patients.

Using Freelite and Hevylite together is the best Multiple Myeloma monitoriing system.

VIsit: www.bindingsite.com